Clinical trial · Interventional
Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial
Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial: Efficacy of a Text-messaging Application in Increasing Adherence With Adjuvant Endocrine Therapy for Stage I-III Hormone Receptor Positive Breast Cancer
NCT02256670CI-TRIAL-00025796completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pilot study to assess feasibility and patient acceptance of a text message cell phone application for patients with stage I-III, hormone receptor positive breast cancer who start adjuvant endocrine therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Text Message Application | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Text Message Application Intervention
- description
- The study intervention will include a mobile phone two-way text message application. Each prompt described below will generate either a yes (Y)/no (N) or ABCDE(F) response from patients. Each response will generate further prompts resulting in either notification for providers to call patients or relevant phone numbers for patients to call for assistance.
- interventionNames
- Behavioral: Text Message Application
Primary outcomes (2)
- measure
- Patient Acceptance of Text Message Program
- timeFrame
- 3 months
- description
- Using self-report surveys to assess feasibility and patient acceptance of text message program
- measure
- Adherence to Endocrine Therapy
- timeFrame
- 3 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed stage I-III, estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines, invasive breast cancer for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines * Patients may enter the study before or within one month of starting endocrine treatment * Patients with synchronous bilateral breast cancers are eligible if both tumors are hormone receptor positive * Patient must be able to provide informed consent and agree to: * Complete questionnaires according to the pre-specified study design * Own a personal cell phone, agree to receive text messages on a monthly basis (including any costs), and share their personal cell phone number to receive text message reminder * sign consent to allow research staff to contact their pharmacies to determine prescription refill dates Exclusion Criteria: * Patients with ductal carcinoma in situ
References
Publications (0)
Data not yet available
No reference posted for this study.